Phathom begins Phase 3 trial of VOQUEZNA as — needed dosing in non — erosive GERD patients
Phathom Pharmaceuticals began screening patients for a registrational Phase 3 trial of VOQUEZNA as-needed dosing in non-erosive GERD. The study aims to show rapid, sustained relief of heartburn episodes with on-demand use, supporting a potential U.S. label expansion. Earlier Phase 2 data were positive; Phase 3 topline